Metraipolis › archive › dc_a4eabdfee8c7

Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis — Europe PMC PMID:42068513

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42068513
DOI
10.1007/s10637-[numero omesso]-1
License (as archived)
solo-consultazione
Archived
2026-10-08T15:46:05.262Z
SHA-256 of the archived text
aae63d595e3a806a628131808992a311a7a6f13dc1c15e1fd8b2ff9608b7ea4f
Stable URL of this page
https://metraipolis.com/documento/dc_a4eabdfee8c7

How to cite

Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis — Europe PMC PMID:42068513 — Europe PMC (en), https://europepmc.org/article/MED/42068513 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a4eabdfee8c7 (Metraipolis archive dc_a4eabdfee8c7, sha256 aae63d595e3a806a628131808992a311a7a6f13dc1c15e1fd8b2ff9608b7ea4f)
BibTeX
@misc{dca4eabdfee8c7,
  title = {Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis — Europe PMC PMID:42068513},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42068513},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a4eabdfee8c7; sha256 aae63d595e3a806a628131808992a311a7a6f13dc1c15e1fd8b2ff9608b7ea4f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42068513. Agents can read the archived copy with the MCP tool read_document.